Ankit Mahadevia

2019

In 2019, Ankit Mahadevia earned a total compensation of $1.8M as Chief Executive Officer at Spero Therapeutics, a 148% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$250,000
Option Awards$752,778
Salary$497,083
Stock Awards$285,023
Other$792
Total$1,785,676

Mahadevia received $752.8K in option awards, accounting for 42% of the total pay in 2019.

Mahadevia also received $250K in non-equity incentive plan, $497.1K in salary, $285K in stock awards and $792 in other compensation.

Rankings

In 2019, Ankit Mahadevia's compensation ranked 6,484th out of 13,971 executives tracked by ExecPay. In other words, Mahadevia earned more than 53.6% of executives.

ClassificationRankingPercentile
All
6,484
out of 13,971
54th
Division
Manufacturing
2,458
out of 5,698
57th
Major group
Chemicals And Allied Products
896
out of 2,197
59th
Industry group
Drugs
760
out of 1,883
60th
Industry
Pharmaceutical Preparations
557
out of 1,395
60th
Source: SEC filing on September 30, 2020.

Mahadevia's colleagues

We found two more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2019.

2019

Christina Larkin

Spero Therapeutics

Chief Operating Officer

2019

David Melnick

Spero Therapeutics

Chief Medical Officer

News

You may also like